Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers

Authors: Caroline van Haaften, Colin C Duke, Arij M Weerheim, Nico PM Smit, Paul MM van Haard, Firouz Darroudi, Baptist JMZ Trimbos

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

Ovarian cancer remains the leading cause of death from gynaecological malignancy. More than 60% of the patients are presenting the disease in stage III or IV. In spite of combination of chemotherapy and surgery the prognosis stays poor for therapy regimen.

Methods

The leaves of a plant endemic to Australia, Calomeria amaranthoides, were extracted and then fractionated by column chromatography. In vitro cytotoxicity tests were performed with fractions of the plant extract and later with an isolated compound on ovarian cancer cell lines, as well as normal fibroblasts at concentrations of 1-100 μg/mL (crude extract) and 1-10 μg/mL (compound). Cytotoxicity was measured after 24, 48 and 72 hours by using a non-fluorescent substrate, Alamar blue.
In vivo cytotoxicity was tested on ascites, developed in the abdomen of nude mice after inoculation with human OVCAR3 cells intraperitoneally. The rate of change in abdomen size for the mice was determined by linear regression and statistically evaluated for significance by the unpaired t test.

Results

Two compounds were isolated by chromatographic fractionation and identified by 1H-NMR, 13C-NMR and mass spectrometry analyses, EPD, an α-methylene sesquiterpene lactone of the eremophilanolide subtype, and EPA, an α-methylene carboxylic acid.
Cytotoxicity of EPD for normal fibroblasts at all time points IC50 was greater than 10 μg/mL, whereas, for OVCAR3 cells at 48 hours IC50 was 5.3 μg/mL (95% confidence interval 4.3 to 6.5 μg/mL).
Both, the crude plant extract as well as EPD killed the cancer cells at a final concentration of 10 μg/mL and 5 μg/mL respectively, while in normal cells only 20% cell killing effect was observed. EPA had no cytotoxic effects.
Changes in abdomen size for control versus Cisplatin treated mice were significantly different, P = 0.023, as were control versus EPD treated mice, P = 0.025, whereas, EPD versus Cisplatin treated mice were not significantly different, P = 0.13.

Conclusions

For the first time both crude plant extract from Calomeria amaranthoides and EPD have been shown to have potent anti-cancer effects against ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ventenat EP: 'Jardin de la Malmaison'. 1804, De Crapelet and Orchard (Paris), 1,2: Ventenat EP: 'Jardin de la Malmaison'. 1804, De Crapelet and Orchard (Paris), 1,2:
2.
go back to reference Smith JE: 'Exotic botany'. 1804, Taylor R & Co. (London), 1: Smith JE: 'Exotic botany'. 1804, Taylor R & Co. (London), 1:
3.
go back to reference Puttock CF: Calomeria. Flora of Victoria. Edited by: Walsh NG and Entwistle TJ. 1993, Melbourne, Inkata Press, 4: Puttock CF: Calomeria. Flora of Victoria. Edited by: Walsh NG and Entwistle TJ. 1993, Melbourne, Inkata Press, 4:
4.
go back to reference Orchard AE: A reassessment of the genus Haeckeria (Asteraceae: Gnaphalieae), with definition of new species in Cassinia. Australian Systematic Botany. 2004, 17: 447-449. 10.1071/SB04021.CrossRef Orchard AE: A reassessment of the genus Haeckeria (Asteraceae: Gnaphalieae), with definition of new species in Cassinia. Australian Systematic Botany. 2004, 17: 447-449. 10.1071/SB04021.CrossRef
5.
go back to reference Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E: Ethnopharmacology of Mexican Asteraceae (Compositae). Annual Reviews. 1998, 38: 539-565. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E: Ethnopharmacology of Mexican Asteraceae (Compositae). Annual Reviews. 1998, 38: 539-565.
6.
go back to reference Zhang S, Won Y-K, Ong C-N, Shen H-M: Anti-Cancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Curr Med Chem-Anti-Cancer Agents. 2005, 5: 239-249. 10.2174/1568011053765976.CrossRef Zhang S, Won Y-K, Ong C-N, Shen H-M: Anti-Cancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Curr Med Chem-Anti-Cancer Agents. 2005, 5: 239-249. 10.2174/1568011053765976.CrossRef
7.
go back to reference Scully RE, Young RH, Clement PB: Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Edited by: Scully RE, Young RH, Clement PB. 1998, Washington, DC, Armed Forces Institute of Pathology, Third: Scully RE, Young RH, Clement PB: Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Edited by: Scully RE, Young RH, Clement PB. 1998, Washington, DC, Armed Forces Institute of Pathology, Third:
8.
go back to reference The Merck Manual of Diagnosis and Therapy, Gynecology And Obstetrics. Gynecol Neoplasms. 2006, 241 (18). The Merck Manual of Diagnosis and Therapy, Gynecology And Obstetrics. Gynecol Neoplasms. 2006, 241 (18).
9.
go back to reference Van Haaften-Day C, Russell P, Rugg C, Wills EJ, Tattersall MHN: Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts. Cancer Res. 1983, 43: 3725-3731.PubMed Van Haaften-Day C, Russell P, Rugg C, Wills EJ, Tattersall MHN: Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts. Cancer Res. 1983, 43: 3725-3731.PubMed
10.
go back to reference Van Haaften-Day C, Russell P, Brammah-Carr S: Two homologous mixed Müllerian tumor lines of the ovary and their characteristics. Cancer. 1990, 65: 1753-1761. 10.1002/1097-0142(19900415)65:8<1753::AID-CNCR2820650816>3.0.CO;2-R.CrossRefPubMed Van Haaften-Day C, Russell P, Brammah-Carr S: Two homologous mixed Müllerian tumor lines of the ovary and their characteristics. Cancer. 1990, 65: 1753-1761. 10.1002/1097-0142(19900415)65:8<1753::AID-CNCR2820650816>3.0.CO;2-R.CrossRefPubMed
11.
go back to reference Van Haaften-Day C, Russell P, Davies S, Brammah-Carr S: An in vitro study of ovarian atypical proliferating (borderline) serous tumors. Int J Gynecol Cancer. 1992, 2: 41-48. 10.1046/j.1525-1438.1992.02010041.x.CrossRefPubMed Van Haaften-Day C, Russell P, Davies S, Brammah-Carr S: An in vitro study of ovarian atypical proliferating (borderline) serous tumors. Int J Gynecol Cancer. 1992, 2: 41-48. 10.1046/j.1525-1438.1992.02010041.x.CrossRefPubMed
12.
go back to reference Brookes S, Rowe J, Ruas M, Llianos S: INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. The EMBO Journal. 2002, 21: 2936-2945. 10.1093/emboj/cdf289.PubMedCentralCrossRefPubMed Brookes S, Rowe J, Ruas M, Llianos S: INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. The EMBO Journal. 2002, 21: 2936-2945. 10.1093/emboj/cdf289.PubMedCentralCrossRefPubMed
13.
go back to reference Pagé B, Pagé M, Noel C: A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol. 1993, 3: 473-476.PubMed Pagé B, Pagé M, Noel C: A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol. 1993, 3: 473-476.PubMed
14.
go back to reference Tanaka N, Yazawa T, Aoyama K, Murakami T: Chemische untersuchungen der inhaltsstoffe von Xanthium canadense Mill. Chem Pharm Bull. 1976, 24: 1419-1421.CrossRef Tanaka N, Yazawa T, Aoyama K, Murakami T: Chemische untersuchungen der inhaltsstoffe von Xanthium canadense Mill. Chem Pharm Bull. 1976, 24: 1419-1421.CrossRef
15.
go back to reference Bohlmann F, Zdero C, Silva M: Two further eremophilane derivatives from Tessaria absynthioides. Phytochem. 1977, 16: 1302-1303. 10.1016/S0031-9422(00)94385-1.CrossRef Bohlmann F, Zdero C, Silva M: Two further eremophilane derivatives from Tessaria absynthioides. Phytochem. 1977, 16: 1302-1303. 10.1016/S0031-9422(00)94385-1.CrossRef
16.
go back to reference Zdero C, Bohlmann F, Anderberg A, King RM: Eremophilane derivates and other constituents from Haeckeria species and further Australian Inuleae. Phytochem. 1991, 30: 2643-2650. 10.1016/0031-9422(91)85114-F.CrossRef Zdero C, Bohlmann F, Anderberg A, King RM: Eremophilane derivates and other constituents from Haeckeria species and further Australian Inuleae. Phytochem. 1991, 30: 2643-2650. 10.1016/0031-9422(91)85114-F.CrossRef
17.
go back to reference NCI: In Vivo Antitumor Screening Data. Cancer Chemotherapy Reports. 1973, 2: 3- NCI: In Vivo Antitumor Screening Data. Cancer Chemotherapy Reports. 1973, 2: 3-
18.
go back to reference Dupuis G, Brisson J: Toxic effect of alantolactone and dihydroalantolactone in in vitro cultures of leukocytes. Chem Biol Interact. 1976, 15: 205-217. 10.1016/0009-2797(76)90147-2.CrossRefPubMed Dupuis G, Brisson J: Toxic effect of alantolactone and dihydroalantolactone in in vitro cultures of leukocytes. Chem Biol Interact. 1976, 15: 205-217. 10.1016/0009-2797(76)90147-2.CrossRefPubMed
19.
go back to reference Markman M: Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin N Am. 2003, 17: 957-968. 10.1016/S0889-8588(03)00058-3.CrossRef Markman M: Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin N Am. 2003, 17: 957-968. 10.1016/S0889-8588(03)00058-3.CrossRef
20.
go back to reference Bookman MA, Greer BE, Ozols RF: Optimal therapy of advanced ovarian cancer: carboplatin and placitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer. 2003, 13: 149-155. 10.1111/j.1525-1438.2003.13362.x.CrossRefPubMed Bookman MA, Greer BE, Ozols RF: Optimal therapy of advanced ovarian cancer: carboplatin and placitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer. 2003, 13: 149-155. 10.1111/j.1525-1438.2003.13362.x.CrossRefPubMed
Metadata
Title
Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers
Authors
Caroline van Haaften
Colin C Duke
Arij M Weerheim
Nico PM Smit
Paul MM van Haard
Firouz Darroudi
Baptist JMZ Trimbos
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-29

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine